Artiva Biotherapeutics (ARTV) Return on Capital Employed (2024 - 2026)

Artiva Biotherapeutics (ARTV) has 3 years of Return on Capital Employed data on file, last reported at 85.59% in Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 4576.0% year-over-year to 85.59% in Q1 2026; TTM through Mar 2026 was 85.59%, a 4576.0% decrease from a year earlier, with the FY2025 full-year figure at 57.14%, down 1077.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 85.59%, down from 70.82% in the prior quarter.
• Over the last five years, Return on Capital Employed for ARTV reached as high as 32.77% in Q4 2024 and fell as low as 85.59% in Q1 2026.
• Historically, Return on Capital Employed has averaged 54.24% across 3 years, with a median of 48.11% in 2025.
• Across the five-year window, Return on Capital Employed sank 1384 bps in 2025 and tumbled 4576 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 32.77% in 2024, then sank by 116 bps to 70.82% in 2025, then declined by 21 bps to 85.59% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 85.59% in Q1 2026, 70.82% in Q4 2025, and 58.2% in Q3 2025.